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ABSTRACT 
For more than a decade, a prevailing hypothesis in research related to arterial disease has been that 
circulating endothelial progenitor cells (EPC) provide protection by their innate ability to replace 
dysfunctional or damaged endothelium. This paradigm has led to extensive investigation of EPCs in 
the hope of finding therapeutic targets to control their homing and differentiation. However from 
the very beginning, the nomenclature and the phenotype of EPCs have been subject to controversy 
and there are currently no specific markers that can unambiguously identify these cells. Moreover, 
many of the initial observations that EPCs differentiate to endothelial cells in the course of arterial 
disease have been criticized for methodological problems. The present review discusses the 
contrasting experimental evidence as to the role of EPCs in contributing to relining of the 
endothelium and highlights some of the methodological pitfalls and terminological ambiguities that 
confuse the field.  
  
Keywords: Endothelial progenitor cells, endothelial cell, atherosclerosis, allograft vasculopathy, 
mechanical injury 
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1. INTRODUCTION 
The healthy endothelium forms a continuous lining of the vascular system that controls 
the passage  of nutrients and oxygen from the blood into tissues, serves removal of 
cellular and metabolic waste products, and regulates arterial reactivity through synthesis 
and release of vasoactive molecules.1 The basal rate of endothelial cell (EC) proliferation 
in healthy blood vessels is low but certain regions display a higher rate.2 Moreover, EC 
proliferation increases with age and the presence of cardiovascular risk factors.3  
Common for cardiovascular diseases is the loss of normal endothelial function. Prolonged 
or exaggerated endothelial activation leads to dysfunction and loss of integrity with 
apoptosis and necrosis.1, 4 At the atherosclerosis-prone regions of the apolipoprotein E 
deficient (apoE-/-) mouse, for example, endothelial turnover rate and proliferation is 
increased early before the development of atherosclerotic plaques.5  
The means whereby the uninterrupted endothelial lining is maintained and regenerated 
have been debated for a long time (Figure 1). In the mid-1900’s, several experiments 
showed that regeneration of damaged endothelium involves EC mitosis.6, 7 However, 
other investigators also reported that the endothelium may be derived from other types of 
cells, including circulating cells in the blood and undifferentiated cells from the 
subendothelial space.8 A number of careful studies in the 1970s further supported the 
dominant role of local EC mitosis and migration in endothelial regeneration after vascular 
damage,3, 9, 10 although they provided little information concerning the actual 
mechanisms that control the movement and proliferation of ECs at injury sites.11 
Additionally, it was shown that small areas of endothelial injury can be repaired solely 
through EC migration while larger areas of injury are repaired by both proliferation and 
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migration.9, 12 These findings are in line with indirect evidence obtained in wound healing 
assays which supports the role of EC proliferation and migration in endothelial repair.13 
Moreover, pathological processes that cause damage to the endothelium can also cause 
detachment of ECs resulting in a very low number of circulating mature ECs in the 
bloodstream which might participate in endothelial repair.14 None of these studies, 
however, were able to determine whether local proliferation is the only mechanism 
underlying EC renewal and regeneration.  
In a landmark study, Asahara and colleagues13 isolated putative endothelial progenitor 
cells (EPC) from the peripheral blood. During short-term culturing, some of these CD34+ 
mononuclear blood cells acquired endothelial-like characteristics, and they homed to sites 
of angiogenesis when injected intravenously into animals with hind limb ischemia. The 
foundation for research in EPC-mediated repair of the endothelium was laid (Figure 1). 
During the last decade, numerous studies have undertaken to define the role of EPCs in 
vascular disease as well as their potential use as a biomarker of cardiovascular disorders. 
However, attempts to identify and describe EPCs and their biological properties have 
yielded conflicting results. As discussed in the present review, much of the controversy 
may be fostered by inconsistent terminology and common methodological pitfalls.  
 
2. ORIGIN AND CHARACTERIZATION OF EPCS 
EPCs can reside in the bone marrow (BM), the peripheral blood, the vascular adventitia 
and/or the endothelium itself.14-16 Their identification and characterization has been based 
on a variety of techniques that fall roughly into two categories: flow cytometric assays for 
cell surface markers and cell culture assays. Asahara and colleagues13 defined EPCs as 
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cells positive for the hematopoietic stem cell (HSC) marker CD34 and the vascular 
endothelial growth factor receptor 2 (VEGFR2 or KDR in humans).  Since CD34 is not 
exclusively expressed in HSCs but also in mature ECs, the immature HSC marker AC133 
has been used to better discriminate between EPCs and mature ECs.17 Both populations 
(CD34+ or AC133+) may differentiate into cells that express EC markers in vitro13, 18 and 
enhance neovascularization when injected in animal models after ischemia.13, 19 However, 
although CD34+VEGFR-2+AC133+ cells are widely accepted to represent “true EPCs” in 
humans,20 they have never been proven to differentiate into ECs in vivo. Moreover, recent 
studies show that mobilized adult peripheral blood CD34+VEGFR-2+AC133+ cells in fact 
represent an enriched population of CD45+ hematopoietic precursors, which do not 
differentiate to ECs in vitro.21  
Based on cell culture assays, two distinct EPC phenotypes derived from human 
peripheral blood mononuclear cells have been described.22 When seeded in culture 
dishes, colonies of cells with an elongated and spindle shape were observed similar to 
that of the EPCs first reported by Asahara and colleagues13. These cells die within four 
weeks and were called “early” EPCs in contrast to a cell population displaying an 
endothelial-like cobblestone shape after two to three weeks, surviving up to twelve weeks 
and named endothelial colony forming cells (ECFCs) or “late” EPCs.23 The rare 
circulating ECFCs were recently found to be CD146+CD34+CD31+CD45-AC133+ cells 
by flow cytometry, similar to mature circulating and resident ECs.24 The origin of ECFCs 
is not yet clear, but similar cells can be identified in primary cultures of umbilical vein 
and aortic ECs, suggesting that they may dislodge into the blood from the vessel wall.25 
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In vivo, both types of EPCs apparently show similar vasculogenic capacity22 but since 
ECFCs have higher proliferation potency and may incorporate into perfused vessels they 
are considered by some to represent true EPCs.26 In a model of hind limb ischemia, 
ECFCs was shown to enhance revascularization in synergy with early EPCs.27 
Recent observations suggest that the formation of “EC” colonies after culture of 
peripheral blood cells, used to demonstrate early EPCs, should be interpreted with 
caution. Prokopi and colleagues demonstrated that conventional methods for isolating 
mononuclear cells after 7 days of culture lead to contamination with platelet 
microparticles (MPs).28 These are taken up in mononuclear cells, which thereby acquire 
artefactual “EC” characteristics such as the presence of CD31 and von Willebrand Factor 
(vWF), binding of lectins and even angiogenic properties.28  
Overall, the use of different marker combinations and culture assays to isolate or measure 
progenitor cells indicate that the term EPC does not represent a single, well-defined cell 
type. Rather, the term is used to describe a number of different and heterogeneous cell 
populations that circulate in the blood or can be derived through short- or long-term 
culturing of blood cells.   
 
3. EPCS AND CARDIOVASCULAR DISEASE 
Consistent with their putative function in endothelial turnover and repair, several reports 
indicate that the concentration of EPCs, defined in various ways, is associated with 
cardiovascular disease. Thus, risk factors for atherosclerosis correlate inversely with the 
number of EPCs in the blood in vivo and with the results of in vitro assays of EPC 
function.29-35 Furthermore, a low number of EPCs, defined as CD34+VEGFR2+ cells, is 
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associated with the presence of coronary artery disease (CAD), and predicts the 
occurrence of cardiovascular events and death from cardiovascular causes in patients.30, 31 
Using flow cytometry and short-term culture assays to measure EPC numbers, similar 
correlations have been obtained between reduced EPC numbers and the extent of 
atherosclerosis in other vascular beds than the coronaries,34 allograft vasculopathy in 
transplanted hearts,33 and diffuse in-stent restenosis after percutaneous coronary 
intervention (PCI).35 By contrast, Güven and colleagues reported that the number of 
EPCs was actually increased among patients with significant CAD when EPCs were 
defined by their ability to give rise to endothelial-cell like colonies during long-term 
culture (late EPCs).36  
Stem cells usually exist in a quiescent state but start to differentiate and to be mobilized 
into the systemic circulation upon specific stimulation. For example, putative EPCs can 
be mobilized in patients with vascular diseases by granulocyte-colony stimulating factor, 
statins or by exercise.37 Whether the associations between EPC number and 
cardiovascular disease reflect alterations in consumption rate or regulation of the release 
of putative EPCs is unknown.  
 
4. IN VIVO EVIDENCE FOR ENDOTHELIAL CELL ORIGIN 
Before classifying cells as EPCs, it is essential to validate their homing and 
differentiation potential in vivo. The ability to produce cells with endothelial 
characteristics in vitro is indicative, but the capacity to incorporate into an endothelial 
lining and conduct EC functions is a far more stringent criterion which cannot be tested 
outside the living organism. If EPCs exist and undertake physiologically relevant repair 
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of the endothelium, it should be possible to detect their contribution by labelling 
circulating cells with a genetic tracking marker and analyse their fate using specific 
markers for phenotype and high-resolution microscopy of the blood vessel wall (Figure 
2).38, 39 This approach also has the advantage that it bypasses the errors involved with 
isolation of EPCs, if they exist, and the confusion regarding appropriate phenotypic 
markers of these cells.  
 
5. EPCS IN MODELS OF ARTERIAL DISEASE  
Most arterial diseases involve injury to or death of ECs.4 During the development of 
atherosclerosis, ECs are continuously injured and replaced (i.e. turnover)1 while under 
other circumstances, EC injury may be more pronounced and cover a larger area to be 
repaired (i.e. regeneration). The process of EC turnover may differ from the one involved 
in endothelial regeneration.  
Circulating EPCs may contribute to the generation of microvascular ECs at sites of 
neovascularization,13, 40 and to relining of the endothelium after various kinds of arterial 
injuries, including mechanical removal,41-43 and allograft vasculopathy,41, 44, 45  as well as 
to vein graft atherosclerosis.46 Although atherosclerosis is by far the most important 
arterial disease worldwide, only few studies have been conducted on the role of putative 
EPCs in the EC turnover associated with this disease.  
 
5.1. EPCs in atherosclerosis 
Only indirect evidence exists supporting the prevailing understanding that circulating 
EPCs provide protection against atherosclerosis by their ability to replace dysfunctional 
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ECs.5, 47 The few studies in which atherosclerotic mice received BM- or blood-derived 
cells assumed to contain EPCs intravenously yielded discrepant results. Thus, Silvestre et 
al.48 and George et al.49 reported that transplantation of BM-derived cells accelerated 
atherosclerosis while Zoll and colleagues50 found that injection of EPCs had no effect on 
the development of the disease.  In yet another study, the intravenous injection of BM-
derived progenitors from young non-atherosclerotic into mature atherosclerotic apoE-/- 
mice exerted a vascular protective effect.51 Some of the injected cells adhered to the 
surface of atherosclerosis-prone areas of the aorta, an observation which lead to the 
suggestion that they may reduce atherosclerosis by replacing senescent ECs in plaques.51 
Others, however, observed that the injection of fluorescently-labeled BM- and spleen-
derived EPCs in apoE-/- mice, resulted in the predominant accumulation of these cells 
within the lipid core of the plaques and not within the endothelium.49  
In a transgenic TIE2-lacZ mouse model of vein graft atherosclerosis expressing β-
galactosidase positive (β-gal+) in ECs, the endothelium was partly repaired by BM-
derived EPCs.46 In vein grafts from TIE2-LacZ mice transplanted into the carotid artery 
of wild-type mice, the number of β-gal+ cells was reduced markedly while such cells 
were evenly distributed on the surface of wild-type vein segments when transplanted into 
TIE2-LacZ mice.46 Moreover, β-gal+ cells were seen on wild-type veins transplanted into 
mice carrying BM cells from TIE2-LacZ mice.46 These data are in line with the 
observation that, in areas prone to lesion development in apoE-/- mice transplanted with 
BM from TIE2-lacZ mice,  3% to 4% of cells displaying progenitor markers were β-gal+.5  
Only one study so far has analyzed the origin of the plaque endothelium during the actual 
development of atherosclerosis in hyperlipidemic apoE-/- mice. Not a single circulatory 
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EPC-derived EC was present at the plaque surface.38 This finding was further 
corroborated by studies of endothelial regeneration after mechanical injury to advanced 
plaques in old apoE-/- mice, where the regenerated endothelium was derived exclusively 
from the local blood vessel wall, presumably through proliferation of flanking ECs 
(Figure 2).38  
Plaque neovascularization may contribute to plaque growth and increase plaque 
vulnerability,52, 53 but due to the lack of animal models featuring plaque neovessels, not 
much are known about the contribution of EPCs to this process.  
 
5.2. EPCs in allograft vasculopathy 
In 2002 Quaini and colleagues54 reported that recipient-derived cardiomyocytes, smooth 
muscle cells and ECs were common in sex-mismatched (female-to-male) heart 
transplants. Multiple studies have been conducted to study this phenomenon in simplified 
rodent models where vessel allografts are transplanted into the arterial system of 
recipients without immunosuppression to protect the donor cells. In these systems, the 
endothelium of the allograft efficiently regenerates with recipient-derived cells. The 
hypothesis that the majority of these recipient-derived cells originates from circulating 
EPCs that home and differentiate into mature ECs in the allografts has attracted particular 
interest.55, 56 Using a mouse model in which the expression of β-gal was regulated by the 
endothelial-specific TIE2 promoter, Hu et al.45 observed that ECs of neointimal lesions in 
allografts of aortic segments are derived from β-gal+ circulating EPCs with 
approximately 30% of ECs being of BM origin.45 By contrast, Hillebrands and 
colleagues44 reported that the contribution of BM-derived EPCs was only minimal (1 to 
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3%) when investigating the origin of ECs by performing orthotopic aortic allografting in 
BM-chimeric recipient rats; they did, however, not determine the potential contribution 
from non-BM-derived EPCs. Taken in conjunction, these studies point to a contribution 
of non-BM- and BM-derived EPCs in transplant atherosclerosis rather than ECs from the 
nearby blood vessel wall, as inferred mainly from the absence of observable inward 
migration fronts of ECs at selected early time points after allografting.44, 45  By contrast, 
the majority of the reported data favors the view that ECs in allografts are derived from 
migrating ECs from the flanking vasculature.9, 10  When an allografted blood vessel or 
heart is interpositioned in a recipient, it is not obvious to ascertain whether cells originate, 
from the flanking vasculature versus circulating EPCs. However, the use of an approach 
that distinguishes between different cell sources (Figure 3) demonstrated that migrating 
vascular ECs rather than circulating EPCs are the source of recipient-derived ECs in a 
murine model of hyperlipidemia-accelerated allograft vasculopathy (AV).39  
 
5.3. EPCs in endothelial regeneration 
Re-endothelialization after mechanical vascular injury, including PCI, is essential for 
inhibition of neointima formation and restoration of vascular homeostasis.57, 58 Several 
studies in experimental models have concluded that circulating EPCs may be involved in 
this process.42, 43, 59-61 Walter et al.42 and Werner et al.43 demonstrated that in mice and 
rats statins facilitated re-endothelialization of injured arterial segments with a resultant 
reduction in neointimal thickening, and that this was associated with an increased 
contribution of EPC-derived ECs mobilized from the BM. Mobilization of EPCs has also 
been implicated in the promoting effect of several other interventions on endothelial 
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regeneration, including estrogen therapy,59 exercise,61 and systemic heme oxygenase 1-
overexpression.60 By contrast, diabetes was found to impair EPC function. Thus, Ii et al. 
reported that transplantation of diabetic BM into non-diabetic mice resulted in delayed re-
endothelialization after wire-induced carotid denudation presumably due to impaired 
incorporation of BM-derived ECs.61  
Other studies, however, have questioned that differentiation of ECs from circulating 
EPCs is the underlying mechanism explaining these findings. Tsuzuki and colleagues62 
concluded to the absence of contribution of BM-derived cells to re-endothelialization in a 
wire-induced endothelial denudation model of the common carotid artery of mice 
transplanted with green fluorescence protein positive (GFP+) BM. Furthermore, Itoh and 
colleagues63 observed that re-endothelialization after injury of a confined area of the pial 
artery occurred by stepwise re-growth of endothelium from the edges of the injured area, 
a pattern that does not permit to accept homing of circulating EPCs as a major 
mechanism for endothelial regeneration. Several studies reporting important 
contributions of EPCs have observed similar patterns of re-growth of endothelium from 
the edges as demonstrated by Evans blue injection.59, 61, 64 
Using a mechanical arterial injury in TIE2-GFP+ transgenic mice, to establish whether 
circulating non-BM-derived EPCs or the nearby healthy endothelium contributed to EC 
regeneration, revealed that endothelial regeneration does not involve homing and 
differentiation of circulating EPCs into ECs.65 Instead, the endothelium regenerated by 
GFP+ cells as a function of time, evolving from the anastomosis sites towards the center 
of the transplant. Thus, endothelial regeneration is mediated by migration and possible 
proliferation of ECs from the adjacent healthy vessel wall. 
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5.4. EPCs and neovascularization 
Circulating cells have been reported to incorporate into and facilitate neovascularization 
of ischemic tissues.40, 66 In ischemic hindlimbs of mice transplanted with BM cells 
expressing lacZ under the regulation of an EC lineage-specific promoter (Flk-1 or Tie-2), 
Asahara et al. found lacZ+ cells to be incorporated into capillaries between skeletal 
myocytes.40 Moreover, after ligation of the left coronary artery, EPCs were found to be 
incorporated into foci of neovascularization at the border of the infarct.40 Circulating 
EPCs have also been reported to contribute to the endothelial lining of microvessels in 
wound healing,67 tumor growth,40 and corneal neovascularization.68  
The observation that BM-derived EPCs may facilitate and incorporate into neovessels in 
ischemic muscle offers hope that one could harness this mechanism to treat chronic 
refractory myocardial ischemia or improve functional recovery after myocardial 
infarction.69, 70  
Using a variety of cell sources and delivery strategies, the effect of transplanting 
autologous BM-derived cells to the suffering myocardium has been tested in clinical 
studies. Some of these, but not all,69 have shown significant improvements in specified 
endpoints such as angina frequency or exercise tolerance.71 Whether the positive effects, 
when observed, involve stable integration of the transplanted cells and differentiation to 
ECs has been debated. Putative EPCs have been shown to be able to facilitate 
neovascularization through secretion of paracrine factors66, 72, 73; e.g. injecting EPC-
conditioned medium alone into a rat model of chronic hindlimb ischemia  increased 
capillary density, blood flow and muscle performance significantly.73 Whether mediated 
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by paracrine signaling or not, experiments in both myocardial infarction and limb 
ischemia models have shown that persistence of the transplanted EPCs and their 
differentiation to eNOS expressing cells are necessary for functional improvement.74, 75 
 
 
6. METHODOLOGICAL CHALLENGES 
The seminal descriptions of circulating EPCs have inspired a large number of studies 
investigating various aspects of this cell population, including their phenotypic 
characterization, mobilization and homing, and their value as a blood biomarker of 
vascular health.15, 17, 18, 21, 22, 29-31, 41 A number of those, however, have fundamentally 
questioned the theory that these “EPCs” act as a source of arterial endothelium in vivo 
and have pointed out a number of potential methodological pitfalls that may have led to 
incorrect conclusions.14, 16, 20, 21, 28, 38, 39, 65, 76-79 The key methodological issues in the EPC 
field are probably not different from those initiating other controversies in the progenitor 
cell field being rooted in the failure to reach clear single-cell resolution, and in the use of 
unspecific cell markers or detection systems.38, 80  
Detection of EPC contribution to the endothelium has been based on models in which a 
population of cells, e.g. BM or circulating cells, assumed to be enriched for EPCs, is 
tagged with a transgene encoding a reporter molecule, such as eGFP or -gal. 
Incorporation of tagged cells in the endothelial lining and their expression of 
characteristic endothelial proteins is the criterion used to detect EPC-derived arterial ECs. 
In many vascular diseases, homing of BM-derived cells is an inherent part of the 
pathophysiological process. After vascular injury, hematopoietic cells may transiently 
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cover the denuded area before being replaced by regenerated endothelium16, and such 
cells may easily be mistaken for BM-derived ECs early after injury. Furthermore, in 
atherosclerosis, there is an ongoing passage of BM-derived inflammatory cells through 
the endothelial layer. Moreover, some of these cells may reside in the subendothelial 
space in close proximity to ECs.38, 81 Choi and colleagues82 have shown that dendritic 
cells are abundant in the normal mouse aorta and localized beneath the endothelium in 
the subintimal space. Moreover, dendritic cells are abundant in the intima of 
atherosclerosis-predisposed regions of the wild-type C57BL/6 mouse aorta.83 If clear 
single-cell resolution is not reached, a dendritic or other BM-derived cell lying close to 
an EC, may appear as a single BM-derived EC. Furthermore, the use of widefield rather 
than confocal microscopy can contribute to the above problem since it is not possible to 
visualize thin optical sections of cells in tissue sections when using the former. A cell 
with a tracking marker overlying a cell with a phenotypic marker can therefore be 
misinterpreted as “co-localization”. 
The choice of markers to establish EC type is equally important. A number of studies 
have used CD31 as an EC marker, but since this protein is also expressed by monocytes84 
the detection of BM-derived CD31+ cells is not surprising. More specific markers such as 
vascular endothelial (VE)-cadherin, endothelial nitric oxide synthase (eNOS) and vWF 
should be used as markers for ECs. Even though vWF is also found in platelets and in the 
subendothelial extracellular space, it is specific for ECs when identified within nucleated 
cells in the arterial wall, typically with a characteristic granular cytoplasmic staining 
pattern.85  
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Reporter transgenes driven by the endothelial-specific angiopoietin receptor TIE2 
promoter have often been used to track BM derived ECs.5, 40, 42, 46, 59, 86, 87 The use of a 
reporter molecule that is only expressed in cells of the endothelial lineage obviates the 
need for single-cell resolution, but puts great dependence on the endothelial specificity of 
the promoter. However, a subpopulation of monocytes that circulates in the peripheral 
blood and is recruited to sites of angiogenesis and in regenerating tissues also expresses 
TIE2.88, 89 These cells localize in close proximity to ECs and can therefore easily be 
mistaken for BM-derived ECs. 
 
7. EPC OR ONLY PUTATIVE EPC 
As said above, in most arterial diseases inflammation takes place, in which mobilization, 
circulation, homing, and local differentiation of BM-derived leukocytes play important 
roles in disease progression. Since many EPC populations contain monocytes, it therefore 
can be expected that when injecting putative EPC populations into animals some of these 
cells will home to sites of vascular damage. Dil-Ac-LDL uptake and lectin binding 
together with endothelial marker expression is the phenotypic profile that is commonly 
used for EPC identification. However, monocytes express a similar phenotypic profile 
when cultured under specific conditions in vitro. When Rohde and colleagues,77 cultured 
monocytes for four to six days under angiogenic conditions, the cells lost CD14/CD45 
and displayed a commonly accepted EPC phenotype [including LDL uptake, lectin 
binding, CD31/CD105/CD144 expression and formation of cord-like structures] that 
made them indistinguishable from putative EPCs. These characteristics of 
monocytes/macrophages have also been reported by others.78, 90 Noticeably, monocytes 
already express most tested endothelial genes and proteins at even higher levels than the 
CVR‐2012‐159R1 
17 
 
so-called EPCs, and colony-forming unit ECs (CFU-EC) formation is strictly dependent 
on monocyte presence.77 The putative EPC population of colony-forming mononuclear 
cells in human peripheral blood, similar to those described by Asahara and colleagues in 
mice13, 40, later appeared to be composed mainly of inflammatory and immune 
mononuclear cells rather than true EPCs20, 26, 76, 77, 91, 92 and such cells home to sites of 
arterial injury and atherosclerosis.  
 
8. PARACRINE EFFECT 
An alternative explanation for the association between EPCs and endothelial regeneration 
may be that some of the cells contained in the “EPC” cell populations exert pro-
angiogenic paracrine effects without actually differentiating into ECs.20, 81, 89, 91 They may 
adhere and migrate through the endothelium into the blood vessel wall and there release 
growth factors and chemokines that stimulate endothelial regeneration by resident ECs. 
Putative “EPCs” obtained in short-term culture assays (early EPCs) express 
monocyte/macrophage markers and secrete multiple potent angiogenic growth factors76 
that enhance EC migration93 and protect against oxidative stress-induced apoptosis.94 
Consistent with such paracrine function, serial injections of conditioned media harvested 
from peripheral blood-derived EPCs into an ischemic hind limb ameliorated local 
perfusion by promoting neovascularisation and vascular maturation.95 TIE2-expressing 
monocytes have been reported to exert similar functions. Indeed, during tumor 
angiogenesis, TIE2+ monocytes are located adjacent to new blood vessels without 
integrating into the endothelium.89 Induced apoptosis of these cells through activation of 
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a suicide gene blocked tumor angiogenesis indicating that they stimulate angiogenesis 
though paracrine signaling.89  
The term EPC was initially used in the literally correct way for immature precursor cells 
capable of differentiating into mature ECs in vivo.13, 40-44, 46 Now the term has gradually 
been redefined to include circulating angiogenic cells without an endothelial fate. Thus, 
an alternative explanation for the conflicting results reported in the literature could be due 
to paracrine signaling to local ECs by blood -derived pro-angiogenic cells.79 However, to 
avoid confusion, the literally correct definition of a progenitor cell as an immature 
precursor cell capable of differentiating into a mature cell type in vivo should be retained.  
 
9. CONCLUSION 
After more than ten years of enthusiastic research in EPC biology, researchers worldwide 
still do not agree on how this cell population should be defined. Despite the fact that a 
number of studies show an inverse correlation between the number and functional 
activity of EPCs in the blood and the development of cardiovascular disease, this 
correlation does not imply causation.  
The present review has identified limitations and pitfalls in the EPC literature and also 
pointed out methodological challenges. Although there have been numerous attempts to 
define the exact EPC phenotype it has become obvious instead that one deals with a 
heterogeneous population of cells with different phenotypes and in vitro potential. Instead 
of being cells that differentiate into ECs, these putative EPCs rather represent a 
population of monocytes sharing many characteristics of ECs in vitro and in vivo affect 
existing cells through paracrine mechanisms. These putative EPCs do not contribute 
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directly to regeneration of the endothelium in arterial diseases. Thus, as of today, the 
paradigm from the 1970s, which states that ECs in arterial disease are repaired and 
regenerated by proliferation and migration of ECs from the local and adjacent 
vasculature, remains valid. The time probably has come to abandon the term EPC and 
instead to focus more on investigating the paracrine potential of this heterogeneous 
population of cells and the mechanisms responsible for EC proliferation and migration 
from the existing endothelium.  
 
FUNDING 
This work was supported by The Danish Council for Independent Research, Medical 
Sciences. 
 
CONFLICT OF INTEREST 
None. 
 
 
 
 
 
 
 
 
 
 
CVR‐2012‐159R1 
20 
 
REFERENCES 
(1)  Vanhoutte PM. Regeneration of the endothelium in vascular injury. Cardiovasc 
Drugs Ther 2010;24:299-303. 
(2)  Schwartz SM, Benditt EP. Clustering of replicating cells in aortic endothelium. 
Proc Natl Acad Sci U S A 1976;73:651-653. 
(3)  Schwartz SM, Gajdusek CM, Reidy MA, Selden SC, III, Haudenschild CC. 
Maintenance of integrity in aortic endothelium. Fed Proc 1980;39:2618-2625. 
(4)  Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol 2006;47:C7-C12. 
(5)  Foteinos G, Hu Y, Xiao Q, Metzler B, Xu Q. Rapid endothelial turnover in 
atherosclerosis-prone areas coincides with stem cell repair in apolipoprotein E-
deficient mice. Circulation 2008;117:1856-1863. 
(6)  Poole JC, Sanders AG, Florey HW. The regeneration of aortic endothelium. J 
Pathol Bacteriol 1958;75:133-143. 
(7)  Spaet TH, Lejnieks I. Mitotic activity of rabbit blood vessels. Proc Soc Exp Biol 
Med 1967;125:1197-1201. 
(8)  Ts'ao C. Myointimal cells as a possible source of replacement for endothelial cells 
in the rabbit. Circ Res 1968;23:671-682. 
(9)  Schwartz SM, Haudenschild CC, Eddy EM. Endothelial regneration. I. Quantitative 
analysis of initial stages of endothelial regeneration in rat aortic intima. Lab Invest 
1978;38:568-580. 
(10)  Clopath P, Muller K, Staubli W, Burk RR. In vivo and in vitro studies on 
endothelial regeneration. Haemostasis 1979;8:149-157. 
(11)  Schwartz SM, Gajdusek CM, Selden SC, III. Vascular wall growth control: the role 
of the endothelium. Arteriosclerosis 1981;1:107-126. 
(12)  Reidy MA, Schwartz SM. Endothelial regeneration. III. Time course of intimal 
changes after small defined injury to rat aortic endothelium. Lab Invest 
1981;44:301-308. 
(13)  Asahara T, Murohara T, Sullivan A, Silver M, van der ZR, Li T et al. Isolation of 
putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-967. 
(14)  Rabelink TJ, de Boer HC, de Koning EJ, van Zonneveld AJ. Endothelial progenitor 
cells: more than an inflammatory response? Arterioscler Thromb Vasc Biol 
2004;24:834-838. 
CVR‐2012‐159R1 
21 
 
(15)  Urbich C, Dimmeler S. Endothelial progenitor cells functional characterization. 
Trends Cardiovasc Med 2004;14:318-322. 
(16)  Yoder MC. Is endothelium the origin of endothelial progenitor cells? Arterioscler 
Thromb Vasc Biol 2010;30:1094-1103. 
(17)  Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M et al. Expression of 
VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population 
of functional endothelial precursors. Blood 2000;95:952-958. 
(18)  Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M et al. In vitro 
differentiation of endothelial cells from AC133-positive progenitor cells. Blood 
2000;95:3106-3112. 
(19)  Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J et al. 
Neovascularization of ischemic myocardium by human bone-marrow-derived 
angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves 
cardiac function. Nat Med 2001;7:430-436. 
(20)  Timmermans F, Plum J, Yoder MC, Ingram DA, Vandekerckhove B, Case J. 
Endothelial progenitor cells: identity defined? J Cell Mol Med 2009;13:87-102. 
(21)  Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR et al. Human 
CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, 
primitive hematopoietic progenitors. Exp Hematol 2007;35:1109-1118. 
(22)  Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK et al. Characterization of 
two types of endothelial progenitor cells and their different contributions to 
neovasculogenesis. Arterioscler Thromb Vasc Biol 2004;24:288-293. 
(23)  Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, Mortell K et al. 
Identification of a novel hierarchy of endothelial progenitor cells using human 
peripheral and umbilical cord blood. Blood 2004;104:2752-2760. 
(24)  Mund JA, Estes ML, Yoder MC, Ingram DA, Jr., Case J. Flow Cytometric 
Identification and Functional Characterization of Immature and Mature Circulating 
Endothelial Cells. Arterioscler Thromb Vasc Biol 2012;32:1045-1053. 
(25)  Ingram DA, Mead LE, Moore DB, Woodard W, Fenoglio A, Yoder MC. Vessel 
wall-derived endothelial cells rapidly proliferate because they contain a complete 
hierarchy of endothelial progenitor cells. Blood 2005;105:2783-2786. 
(26)  Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F et al. Redefining 
endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor 
cell principals. Blood 2007;109:1801-1809. 
(27)  Yoon CH, Hur J, Park KW, Kim JH, Lee CS, Oh IY et al. Synergistic 
neovascularization by mixed transplantation of early endothelial progenitor cells 
CVR‐2012‐159R1 
22 
 
and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix 
metalloproteinases. Circulation 2005;112:1618-1627. 
(28)  Prokopi M, Pula G, Mayr U, Devue C, Gallagher J, Xiao Q et al. Proteomic 
analysis reveals presence of platelet microparticles in endothelial progenitor cell 
cultures. Blood 2009;114:723-732. 
(29)  Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA et al. 
Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. 
N Engl J Med 2003;348:593-600. 
(30)  Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A et al. Circulating 
endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 
2005;353:999-1007. 
(31)  Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H et al. Number and 
migratory activity of circulating endothelial progenitor cells inversely correlate 
with risk factors for coronary artery disease. Circ Res 2001;89:E1-E7. 
(32)  Chironi G, Walch L, Pernollet MG, Gariepy J, Levenson J, Rendu F et al. 
Decreased number of circulating CD34+KDR+ cells in asymptomatic subjects with 
preclinical atherosclerosis. Atherosclerosis 2007;191:115-120. 
(33)  Simper D, Wang S, Deb A, Holmes D, McGregor C, Frantz R et al. Endothelial 
progenitor cells are decreased in blood of cardiac allograft patients with 
vasculopathy and endothelial cells of noncardiac origin are enriched in transplant 
atherosclerosis. Circulation 2003;108:143-149. 
(34)  Fadini GP, Sartore S, Albiero M, Baesso I, Murphy E, Menegolo M et al. Number 
and function of endothelial progenitor cells as a marker of severity for diabetic 
vasculopathy. Arterioscler Thromb Vasc Biol 2006;26:2140-2146. 
(35)  George J, Herz I, Goldstein E, Abashidze S, Deutch V, Finkelstein A et al. Number 
and adhesive properties of circulating endothelial progenitor cells in patients with 
in-stent restenosis. Arterioscler Thromb Vasc Biol 2003;23:e57-e60. 
(36)  Guven H, Shepherd RM, Bach RG, Capoccia BJ, Link DC. The number of 
endothelial progenitor cell colonies in the blood is increased in patients with 
angiographically significant coronary artery disease. J Am Coll Cardiol 
2006;48:1579-1587. 
(37)  Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM et al. Increase in 
circulating endothelial progenitor cells by statin therapy in patients with stable 
coronary artery disease. Circulation 2001;103:2885-2890. 
(38)  Hagensen MK, Shim J, Thim T, Falk E, Bentzon JF. Circulating endothelial 
progenitor cells do not contribute to plaque endothelium in murine atherosclerosis. 
Circulation 2010;121:898-905. 
CVR‐2012‐159R1 
23 
 
(39)  Hagensen MK, Shim J, Falk E, Bentzon JF. Flanking recipient vasculature, not 
circulating progenitor cells, contributes to endothelium and smooth muscle in 
murine allograft vasculopathy. Arterioscler Thromb Vasc Biol 2011;31:808-813. 
(40)  Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M et al. Bone 
marrow origin of endothelial progenitor cells responsible for postnatal 
vasculogenesis in physiological and pathological neovascularization. Circ Res 
1999;85:221-228. 
(41)  Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T et al. Hematopoietic 
stem cells differentiate into vascular cells that participate in the pathogenesis of 
atherosclerosis. Nat Med 2002;8:403-409. 
(42)  Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T et al. 
Statin therapy accelerates reendothelialization: a novel effect involving 
mobilization and incorporation of bone marrow-derived endothelial progenitor 
cells. Circulation 2002;105:3017-3024. 
(43)  Werner N, Priller J, Laufs U, Endres M, Bohm M, Dirnagl U et al. Bone marrow-
derived progenitor cells modulate vascular reendothelialization and neointimal 
formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. 
Arterioscler Thromb Vasc Biol 2002;22:1567-1572. 
(44)  Hillebrands JL, Klatter FA, van Dijk WD, Rozing J. Bone marrow does not 
contribute substantially to endothelial-cell replacement in transplant 
arteriosclerosis. Nat Med 2002;8:194-195. 
(45)  Hu Y, Davison F, Zhang Z, Xu Q. Endothelial replacement and angiogenesis in 
arteriosclerotic lesions of allografts are contributed by circulating progenitor cells. 
Circulation 2003;108:3122-3127. 
(46)  Xu Q, Zhang Z, Davison F, Hu Y. Circulating progenitor cells regenerate 
endothelium of vein graft atherosclerosis, which is diminished in ApoE-deficient 
mice. Circ Res 2003;93:e76-e86. 
(47)  Werner N, Nickenig G. Influence of cardiovascular risk factors on endothelial 
progenitor cells: limitations for therapy? Arterioscler Thromb Vasc Biol 
2006;26:257-266. 
(48)  Silvestre JS, Gojova A, Brun V, Potteaux S, Esposito B, Duriez M et al. 
Transplantation of bone marrow-derived mononuclear cells in ischemic 
apolipoprotein E-knockout mice accelerates atherosclerosis without altering plaque 
composition. Circulation 2003;108:2839-2842. 
(49)  George J, Afek A, Abashidze A, Shmilovich H, Deutsch V, Kopolovich J et al. 
Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic 
plaque size and composition in apolipoprotein E knockout mice. Arterioscler 
Thromb Vasc Biol 2005;25:2636-2641. 
CVR‐2012‐159R1 
24 
 
(50)  Zoll J, Fontaine V, Gourdy P, Barateau V, Vilar J, Leroyer A et al. Role of human 
smooth muscle cell progenitors in atherosclerotic plaque development and 
composition. Cardiovasc Res 2008;77:471-480. 
(51)  Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D, 
Ramaswami P et al. Aging, progenitor cell exhaustion, and atherosclerosis. 
Circulation 2003;108:457-463. 
(52)  Langheinrich AC, Kampschulte M, Buch T, Bohle RM. Vasa vasorum and 
atherosclerosis - Quid novi? Thromb Haemost 2007;97:873-879. 
(53)  Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma 
SK et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions 
of human aorta: implications for plaque vulnerability. Circulation 2004;110:2032-
2038. 
(54)  Quaini F, Urbanek K, Beltrami AP, Finato N, Beltrami CA, Nadal-Ginard B et al. 
Chimerism of the transplanted heart. N Engl J Med 2002 January 3;346:5-15. 
(55)  Mitchell RN, Libby P. Vascular remodeling in transplant vasculopathy. Circ Res 
2007;100:967-978. 
(56)  Xu Q. Stem cells and transplant arteriosclerosis. Circ Res 2008;102:1011-1024. 
(57)  Asahara T, Bauters C, Pastore C, Kearney M, Rossow S, Bunting S et al. Local 
delivery of vascular endothelial growth factor accelerates reendothelialization and 
attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 
1995;91:2793-2801. 
(58)  Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for 
restenosis. A special case of atherosclerosis progression. Circulation 1992;86:III47-
III52. 
(59)  Iwakura A, Luedemann C, Shastry S, Hanley A, Kearney M, Aikawa R et al. 
Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of 
bone marrow-derived endothelial progenitor cells contributes to 
reendothelialization after arterial injury. Circulation 2003;108:3115-3121. 
(60)  Lin HH, Chen YH, Yet SF, Chau LY. After vascular injury, heme oxygenase-
1/carbon monoxide enhances re-endothelialization via promoting mobilization of 
circulating endothelial progenitor cells. J Thromb Haemost 2009;7:1401-1408. 
(61)  Ii M, Takenaka H, Asai J, Ibusuki K, Mizukami Y, Maruyama K et al. Endothelial 
progenitor thrombospondin-1 mediates diabetes-induced delay in 
reendothelialization following arterial injury. Circ Res 2006;98:697-704. 
CVR‐2012‐159R1 
25 
 
(62)  Tsuzuki M. Bone marrow-derived cells are not involved in reendothelialized 
endothelium as endothelial cells after simple endothelial denudation in mice. Basic 
Res Cardiol 2009;104:601-611. 
(63)  Itoh Y, Toriumi H, Yamada S, Hoshino H, Suzuki N. Resident endothelial cells 
surrounding damaged arterial endothelium reendothelialize the lesion. Arterioscler 
Thromb Vasc Biol 2010;30:1725-1732. 
(64)  Sorrentino SA, Bahlmann FH, Besler C, Muller M, Schulz S, Kirchhoff N et al. 
Oxidant stress impairs in vivo reendothelialization capacity of endothelial 
progenitor cells from patients with type 2 diabetes mellitus: restoration by the 
peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. 
Circulation 2007;116:163-173. 
(65)  Hagensen MK, Raarup MK, Mortensen MB, Thim T, Nyengaard JR, Falk E et al. 
Circulating Endothelial Progenitor Cells Do Not Contribute to Regeneration of 
Endothelium after Murine Arterial Injury. Cardiovasc Res 2011;93:223-231. 
(66)  Ii M, Nishimura H, Iwakura A, Wecker A, Eaton E, Asahara T et al. Endothelial 
progenitor cells are rapidly recruited to myocardium and mediate protective effect 
of ischemic preconditioning via "imported" nitric oxide synthase activity. 
Circulation 2005;111:1114-1120. 
(67)  Bauer SM, Goldstein LJ, Bauer RJ, Chen H, Putt M, Velazquez OC. The bone 
marrow-derived endothelial progenitor cell response is impaired in delayed wound 
healing from ischemia. J Vasc Surg 2006;43:134-141. 
(68)  Murayama T, Tepper OM, Silver M, Ma H, Losordo DW, Isner JM et al. 
Determination of bone marrow-derived endothelial progenitor cell significance in 
angiogenic growth factor-induced neovascularization in vivo. Exp Hematol 
2002;30:967-972. 
(69)  Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX et al. Effect of 
Transendocardial Delivery of Autologous Bone Marrow Mononuclear Cells on 
Functional Capacity, Left Ventricular Function, and Perfusion in Chronic Heart 
Failure: The FOCUS-CCTRN Trial. JAMA 2012 March 24. 
(70)  Lipinski MJ, Biondi-Zoccai GG, Abbate A, Khianey R, Sheiban I, Bartunek J et al. 
Impact of intracoronary cell therapy on left ventricular function in the setting of 
acute myocardial infarction: a collaborative systematic review and meta-analysis of 
controlled clinical trials. J Am Coll Cardiol 2007;50:1761-1767. 
(71)  Losordo DW, Henry TD, Davidson C, Sup LJ, Costa MA, Bass T et al. 
Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res 
2011;109:428-436. 
CVR‐2012‐159R1 
26 
 
(72)  Miyamoto Y, Suyama T, Yashita T, Akimaru H, Kurata H. Bone marrow 
subpopulations contain distinct types of endothelial progenitor cells and angiogenic 
cytokine-producing cells. J Mol Cell Cardiol 2007;43:627-635. 
(73)  Di SS, Yang Z, Wyler von BM, Voelzmann J, Diehm N, Baumgartner I et al. Novel 
cell-free strategy for therapeutic angiogenesis: in vitro generated conditioned 
medium can replace progenitor cell transplantation. PLoS One 2009;4:e5643. 
(74)  Ziebart T, Yoon CH, Trepels T, Wietelmann A, Braun T, Kiessling F et al. 
Sustained persistence of transplanted proangiogenic cells contributes to 
neovascularization and cardiac function after ischemia. Circ Res 2008;103:1327-
1334. 
(75)  Yoon CH, Koyanagi M, Iekushi K, Seeger F, Urbich C, Zeiher AM et al. 
Mechanism of improved cardiac function after bone marrow mononuclear cell 
therapy: role of cardiovascular lineage commitment. Circulation 2010;121:2001-
2011. 
(76)  Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor 
cells" are derived from monocyte/macrophages and secrete angiogenic growth 
factors. Circulation 2003;107:1164-1169. 
(77)  Rohde E, Malischnik C, Thaler D, Maierhofer T, Linkesch W, Lanzer G et al. 
Blood monocytes mimic endothelial progenitor cells. Stem Cells 2006;24:357-367. 
(78)  Schmeisser A, Garlichs CD, Zhang H, Eskafi S, Graffy C, Ludwig J et al. 
Monocytes coexpress endothelial and macrophagocytic lineage markers and form 
cord-like structures in Matrigel under angiogenic conditions. Cardiovasc Res 
2001;49:671-680. 
(79)  Horrevoets AJ. Angiogenic monocytes: another colorful blow to endothelial 
progenitors. Am J Pathol 2009 May;174:1594-1596. 
(80)  Bentzon JF, Falk E. Circulating smooth muscle progenitor cells in atherosclerosis 
and plaque rupture: current perspective and methods of analysis. Vascul Pharmacol 
2010;52:11-20. 
(81)  Purhonen S, Palm J, Rossi D, Kaskenpaa N, Rajantie I, Yla-Herttuala S et al. Bone 
marrow-derived circulating endothelial precursors do not contribute to vascular 
endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A 
2008;105:6620-6625. 
(82)  Choi JH, Do Y, Cheong C, Koh H, Boscardin SB, Oh YS et al. Identification of 
antigen-presenting dendritic cells in mouse aorta and cardiac valves. J Exp Med 
2009;206:497-505. 
CVR‐2012‐159R1 
27 
 
(83)  Jongstra-Bilen J, Haidari M, Zhu SN, Chen M, Guha D, Cybulsky MI. Low-grade 
chronic inflammation in regions of the normal mouse arterial intima predisposed to 
atherosclerosis. J Exp Med 2006;203:2073-2083. 
(84)  Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of 
endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal 
human tissues. J Histochem Cytochem 2006;54:385-395. 
(85)  Yamamoto K, de W, V, Fearns C, Loskutoff DJ. Tissue distribution and regulation 
of murine von Willebrand factor gene expression in vivo. Blood 1998;92:2791-
2801. 
(86)  Aicher A, Rentsch M, Sasaki K, Ellwart JW, Fandrich F, Siebert R et al. Nonbone 
marrow-derived circulating progenitor cells contribute to postnatal 
neovascularization following tissue ischemia. Circ Res 2007;100:581-589. 
(87)  Ruifrok WP, de Boer RA, Iwakura A, Silver M, Kusano K, Tio RA et al. Estradiol-
induced, endothelial progenitor cell-mediated neovascularization in male mice with 
hind-limb ischemia. Vasc Med 2009;14:29-36. 
(88)  De PM, Venneri MA, Roca C, Naldini L. Targeting exogenous genes to tumor 
angiogenesis by transplantation of genetically modified hematopoietic stem cells. 
Nat Med 2003;9:789-795. 
(89)  De PM, Venneri MA, Galli R, Sergi SL, Politi LS, Sampaolesi M et al. Tie2 
identifies a hematopoietic lineage of proangiogenic monocytes required for tumor 
vessel formation and a mesenchymal population of pericyte progenitors. Cancer 
Cell 2005;8:211-226. 
(90)  Fernandez PB, Lucibello FC, Gehling UM, Lindemann K, Weidner N, Zuzarte ML 
et al. Endothelial-like cells derived from human CD14 positive monocytes. 
Differentiation 2000;65:287-300. 
(91)  Sirker AA, Astroulakis ZM, Hill JM. Vascular progenitor cells and translational 
research: the role of endothelial and smooth muscle progenitor cells in endogenous 
arterial remodelling in the adult. Clin Sci (Lond) 2009;116:283-299. 
(92)  Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of 
endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008;28:1584-1595. 
(93)  Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM et al. 
Soluble factors released by endothelial progenitor cells promote migration of 
endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 
2005;39:733-742. 
(94)  Yang Z, von Ballmoos MW, Faessler D, Voelzmann J, Ortmann J, Diehm N. 
Paracrine factors secreted by endothelial progenitor cells prevent oxidative stress-
induced apoptosis of mature endothelial cells. Atherosclerosis 2010;211:103-109. 
CVR‐2012‐159R1 
28 
 
(95)  Di SS, Yang Z, Wyler von BM, Voelzmann J, Diehm N, Baumgartner I et al. Novel 
cell-free strategy for therapeutic angiogenesis: in vitro generated conditioned 
medium can replace progenitor cell transplantation. PLoS One 2009;4:e5643. 
(96)  Thim T, Hagensen MK, Bentzon JF, Falk E. From vulnerable plaque to 
atherothrombosis. J Intern Med 2008;263:506-516. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CVR‐2012‐159R1 
29 
 
FIGURE LENGENDS 
 
 
Figure 1. Until the first reports of EPCs in the late 1990s, it was generally assumed that 
endothelial repair in arterial disease was exclusively due to proliferation and migration of 
local ECs.  By contrast the EPC theory states that EPCs in the circulating blood 
contribute to endothelial repair by differentiating into ECs. This theory is illustrated here 
in the context of endothelial turnover in an atherosclerotic plaque. Revised from Thim et 
al.96 
 
 
Figure 2. Plaque ECs are derived from the local arterial wall. Revised from Hagensen et 
al.38 a. Experiment to investigate whether or not BM-derived EPCs contribute to plaque 
ECs during atherogenesis, An aortic root plaque from an apoE-/- mouse transplanted with 
BM from an eGFP+apoE-/- mouse. No eGFP+vWF+ double-positive cells are present. b. 
Experiment to investigate whether or not any types of bloodborne EPCs contribute to 
plaque ECs during atherogenesis. A common carotid artery (CCA) segment from an 
apoE-/- mouse was orthotopic transplanted into eGFP+apoE-/- mice (isotransplantation 
except for the eGFP transgene). None of the vWF+ cells are eGFP+. Green indicates 
eGFP; red, vWF; blue, nuclei; gray, DIC; L, lumen; BM, bone marrow; AA, aortic arch; 
CCA, common carotid artery; TCCA, transplanted common carotid artery. Scale 
bars=50µm.  
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Figure 3. Endothelium in allograft vasculopathy (AV) lesions in a murine model is 
derived from ECs migrating into the lesion from the adjacent arterial wall. Revised from 
Hagensen et al.39 To locate the source of the recipient-derived cells, carotid artery 
segments (1.TCCA) were first isografted from apoE-/- B6 mice into eGFP+apoE-/- B6 
mice (a) or from eGFP+apoE-/- B6 mice into apoE-/- B6 mice (b). Four weeks later, the 
isograft was transected, and a BALB/c carotid allograft was inserted end-to-end 
(2.TCCA). a. No co-localization of eGFP+ and vWF+ to individual cells was identified. 
The recipient-derived eGFP+ cells were most likely macrophages. b. Almost all vWF+ 
cells were also eGFP+. Green indicates eGFP; red, vWF; blue, nuclei; gray, DIC; L, 
lumen; CCA, common carotid artery; TCCA, transplanted common carotid artery. Scale 
bars=25µm. 
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